Biotech-focused piece exploring an investigational metabolic therapy for fatty liver disease. It follows emerging clinical developments and their potential implications for cardiometabolic care.
Key Takeaways
- Leerink initiated coverage with an Outperform rating and a $10 price target
- 48-week trial showed weight loss plus reductions in triglycerides and total cholesterol
- Approximately 1% discontinued for adverse events, most were mild to moderate early